Developing a cervical dilator for instrument access during uterine procedures
Some hysteroscopic procedures require cervical dilation, which can cause pain, vasovagal reactions and tissue trauma. Cervical narrowing or an inability to tolerate pain can prevent completion in outpatient settings, and dilation generally requires local anaesthesia.
Amarastesia is developing CerAMvix, a disposable cervical dilator and uterine access device. It is designed to let hysteroscopes and other surgical instruments pass through a soft protective passage during gynaecological procedures.
What stands out about Amarastesia
PitchBook reports a completed US$700,000 grant in May 2026; this is non-dilutive funding, not an equity round.
The company reports CerAMvix testing on animal tissue models in Virginia in October 2024, supporting preclinical device development.
Partnering with HE-Arc engineering on computational studies, simulation and testing for CerAMvix development.
Selected for the fourth DayOne Tech Accelerator cohort in Jura, a 12-month medtech programme announced in October 2024.
CerAMvix won InnovX’s top innovation prize, selected from 30 startups by investors, mentors and industry experts.
Founder Roxana Belciu-Kerns is a board-certified anesthesiologist practicing in New York, with medical licences in New York and Florida.
Before Amarastesia, Roxana Belciu-Kerns founded Orchid Aesthetics Medical Spa, a New York clinical practice.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.